Chow T, Khan D
Clin Rev Allergy Immunol. 2021; 62(3):400-412.
PMID: 34212341
DOI: 10.1007/s12016-021-08872-3.
Chaparro J, Cheng T, Tran U, Andrade R, Brenner S, Hwang G
PLoS One. 2018; 13(3):e0193982.
PMID: 29565998
PMC: 5863946.
DOI: 10.1371/journal.pone.0193982.
Bohm R, Cascorbi I
Front Pharmacol. 2016; 7:396.
PMID: 27818635
PMC: 5073094.
DOI: 10.3389/fphar.2016.00396.
Aung A, Haas D, Hulgan T, Phillips E
Pharmacogenomics. 2014; 15(15):1903-30.
PMID: 25495412
PMC: 4296903.
DOI: 10.2217/pgs.14.147.
Cheng L, You Q, Yin H, Holt M, Franklin C, Ju C
Hepatology. 2008; 49(1):215-26.
PMID: 19111017
PMC: 2636554.
DOI: 10.1002/hep.22585.
Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity.
Alfirevic A, Stalford A, Vilar F, Wilkins E, Park B, Pirmohamed M
Br J Clin Pharmacol. 2003; 55(2):158-65.
PMID: 12580987
PMC: 1894729.
DOI: 10.1046/j.1365-2125.2003.01754.x.
Managing drug reactions to sulfonamides and other drugs in HIV infection: desensitization rather than rechallenge?.
Koopmans P, Burger D
Pharm World Sci. 1999; 20(6):253-7.
PMID: 9972526
DOI: 10.1023/a:1008617019897.
Role of desensitisation for drug hypersensitivity in patients with HIV infection.
Carr A
Drug Saf. 1997; 17(2):119-26.
PMID: 9285202
DOI: 10.2165/00002018-199717020-00004.
Role of viral infections in the induction of adverse drug reactions.
Levy M
Drug Saf. 1997; 16(1):1-8.
PMID: 9010640
DOI: 10.2165/00002018-199716010-00001.
Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia.
Hughes W, Killmar J
Antimicrob Agents Chemother. 1996; 40(4):962-5.
PMID: 8849260
PMC: 163239.
DOI: 10.1128/AAC.40.4.962.
HIV medicine: drug side effects and interactions.
Bates C
Postgrad Med J. 1996; 72(843):30-6.
PMID: 8746282
PMC: 2398321.
DOI: 10.1136/pgmj.72.843.30.
Monitoring of co-trimoxazole concentrations in serum during treatment of pneumocystis carinii pneumonia.
Joos B, Blaser J, Opravil M, Chave J, Luthy R
Antimicrob Agents Chemother. 1995; 39(12):2661-6.
PMID: 8592998
PMC: 163008.
DOI: 10.1128/AAC.39.12.2661.
Effects of 8-aminoquinolines on the ultrastructural morphology of Pneumocystis carinii.
Goheen M, Bartlett M, SHAW M, Queener S, Smith J
Int J Exp Pathol. 1993; 74(4):379-87.
PMID: 8398811
PMC: 2001847.
Adverse effects of drugs used in the management of opportunistic infections associated with HIV infection.
Peters B, Carlin E, Weston R, Loveless S, Sweeney J, Weber J
Drug Saf. 1994; 10(6):439-54.
PMID: 7917073
DOI: 10.2165/00002018-199410060-00003.
Urinary recovery and kinetics of sulphamethoxazole and its metabolites in HIV-seropositive patients and healthy volunteers after a single oral dose of sulphamethoxazole.
van der Ven A, Vree T, Koopmans P, van der Meer J
Br J Clin Pharmacol. 1995; 39(6):621-5.
PMID: 7654479
PMC: 1365073.
DOI: 10.1111/j.1365-2125.1995.tb05721.x.
Clinical aspects of the acquired immune deficiency syndrome in the United Kingdom.
Weber J, Carmichael D, Sawyer N, Pinching A, Harris J
Br J Vener Dis. 1984; 60(4):253-7.
PMID: 6744012
PMC: 1046321.
DOI: 10.1136/sti.60.4.253.
Pneumocystis carinii pneumonia treated with alpha-difluoromethylornithine. A prospective study among patients with the acquired immunodeficiency syndrome.
Golden J, SJOERDSMA A, Santi D
West J Med. 1984; 141(5):613-23.
PMID: 6440364
PMC: 1011166.
Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis.
Hughes W, Smith B
Antimicrob Agents Chemother. 1984; 26(4):436-40.
PMID: 6335017
PMC: 179940.
DOI: 10.1128/AAC.26.4.436.
The acquired immune deficiency syndrome: an international health problem of increasing importance.
Wofsy C, Mills J
Klin Wochenschr. 1984; 62(11):512-22.
PMID: 6332236
DOI: 10.1007/BF01727745.
Early experience and difficulties with bronchoalveolar lavage and transbronchial biopsy in the diagnosis of AIDS associated pneumonia in Britain.
Swinburn C, Pozniak A, Sutherland S, Banks R, Teall A, Johnson N
Thorax. 1985; 40(3):166-70.
PMID: 3872484
PMC: 460017.
DOI: 10.1136/thx.40.3.166.